1. Home
  2. HCWB vs XAIR Comparison

HCWB vs XAIR Comparison

Compare HCWB & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.16

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$2.24

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCWB
XAIR
Founded
2018
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
HCWB
XAIR
Price
$1.16
$2.24
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $20.00
AVG Volume (30 Days)
★ 751.6K
57.7K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$4,099,750.00
★ $7,679,000.00
Revenue This Year
$12,215.61
$4.23
Revenue Next Year
N/A
$108.84
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 107.26
52 Week Low
$0.86
$0.33
52 Week High
$24.42
$8.19

Technical Indicators

Market Signals
Indicator
HCWB
XAIR
Relative Strength Index (RSI) 26.99 38.69
Support Level $1.14 $2.05
Resistance Level $1.73 $2.66
Average True Range (ATR) 0.11 0.19
MACD 0.00 0.04
Stochastic Oscillator 1.70 27.66

Price Performance

Historical Comparison
HCWB
XAIR

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Share on Social Networks: